XML 48 R28.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE I - CONDENSED FINANCIAL INFORMATION OF REGISTRANT
 12 Months Ended
Dec. 31, 2021
Condensed Financial Information Disclosure [Abstract]  
SCHEDULE I - CONDENSED FINANCIAL INFORMATION OF REGISTRANT
CONVEY HEALTH SOLUTIONS HOLDINGS, INC.
PARENT COMPANY ONLY
CONDENSED BALANCE SHEETS
(in thousands, except per share data)


December 31, 2021December 31, 2020
ASSETS
Investment in subsidiaries$546,372 $470,285 
Total assets$546,372 $470,285 
LIABILITIES AND SHAREHOLDER’S EQUITY
Intercompany payables to subsidiaries$8,623 $135 
Common stock, $0.01 par value, 500,000,000 and 126,000,000 shares authorized and 73,194,171 and 61,321,424 shares issued and outstanding at December 31, 2021 and 2020, respectively
732 613 
Additional paid-in capital570,252 492,747 
Accumulated other comprehensive income31 78 
Accumulated deficit(33,266)(23,288)
Total shareholder’s equity537,749 470,150 
Total liabilities and shareholder’s equity$546,372 $470,285 
SCHEDULE I - CONDENSED FINANCIAL INFORMATION OF REGISTRANT

CONVEY HEALTH SOLUTIONS HOLDINGS, INC. (SUCCESSOR)
CONVEY HEALTH PARENT, INC. (PREDECESSOR)
PARENT COMPANY ONLY
CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(in thousands)

Years Ended December 31,Period from Inception to December 31,2019Period from January 1, 2019 to September 3, 2019
20212020(Successor)(Predecessor)
Equity in income (loss) of subsidiaries$2,890 $314 $(2,721)$3,949 
Operating expenses(12,868)(6,776)(14,105)(300)
Net (loss) income(9,978)(6,462)(16,826)3,649 
Equity in other comprehensive income (loss) of subsidiaries(47)57 21 (15)
Comprehensive (loss) income$(10,025)$(6,405)$(16,805)$3,634 
CONVEY HEALTH SOLUTIONS HOLDINGS, INC. (SUCCESSOR)
CONVEY HEALTH PARENT, INC. (PREDECESSOR)
PARENT COMPANY ONLY
CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
Years Ended December 31,Period from Inception to December 31,2019Period from January 1, 2019 to September 3, 2019
20212020(Successor)(Predecessor)
Net cash used in operating activities$— $— $(14,064)$— 
Cash flows from investing activities
Investment in subsidiaries— — (433,287)— 
Nest cash used in investing activities— — (433,287)— 
Cash flows from financing activities
Proceeds from capitalization— — 447,351 — 
Net cash provided by financing activities— — 447,351 — 
Net increase in cash and cash equivalents and restricted cash— — — — 
Cash, cash equivalents and restricted cash at beginning of period— — — — 
Cash, cash equivalents and restricted cash at end of period$— $— $— $— 
Non-cash investing and financial activities
Common stock issued in exchange to Parent for the acquisitions$— $— $39,327 $— 
SCHEDULE I - CONDENSED FINANCIAL INFORMATION OF REGISTRANT

Note to Registrant’s Condensed Financial Statements (Parent Company Only)
Basis of Presentation
These condensed parent company financial statements of Convey Health Solutions Holdings, Inc. (Successor) and Convey Health Parent, Inc. (Predecessor) have been prepared in accordance with Rule 12-04 of Regulation S-X, as the restricted net assets of the subsidiaries of Convey Health Solutions Holdings, Inc. (Successor) and Convey Health Parent, Inc. (Predecessor) exceed 25% of the consolidated net assets of Convey Health Solutions Holdings, Inc. (Successor) and Convey Health Parent, Inc. (Predecessor) as stipulated by Rule 5-04, Section 1 from Regulation S-X.
The ability to pay dividends by subsidiaries of Convey Health Solutions Holdings, Inc. (Successor) and Convey Health Parent, Inc. (Predecessor) may be restricted due to the terms of the Credit Agreement, as described in Note 9. Credit Facility, in the consolidated financial statements.
These condensed parent company financial statements have been prepared using the same accounting principles and policies described in the notes to the consolidated financial statements, with the only exception being that Convey Health Solutions Holdings, Inc. (Successor) and Convey Health Parent, Inc. (Predecessor) account for investments in their subsidiaries using the equity method. These condensed parent company financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this report.